Abstract:A group of pediatricians and pulmonologists from the largest referral centers for cystic fibrosis (CF) in Brazil has questioned whether there are genetic, clinical, and treatment distinctions among the different regions of the country. They choose to create a patient registry to compile the characteristics of CF patients in the various regions of Brazil. A few years later, some of these investigators used data from the registry to study the most common types of mutations leading to CF in Brazil and regional differences regarding accessibility to genetic testing. 1 1 da Silva Filho LVRF, Maróstica PJC, Athanazio RA, Reis FJC, Damaceno N, Paes AT, et al. Extensive CFTR sequencing through NGS in Brazilian individuals with cystic fibrosis: unravelling regional discrepancies in the country. J Cyst Fibros. 2021;20(3):473-484. https://doi.org/10.1016/j.jcf.2020.08.007 https://doi.org/10.1016/j.jcf.2020.08.00... A patient registry is an organized data system in which data is systematically collected over time for a population with a specific disease, condition, or outcome. Patient registries include real world data, potentially providing a realistic image of the target population's characteristics, treatments, and outcomes. Data are collected periodically and in a timeline that can be used to study the natural course of diseases and changes in the patterns of care over time. Reports of aggregate data are created and made widely available to the public and medical community. Patient registries are especially helpful in evaluating rare diseases because they typically include data from patients at different medical centers and in several regions of a country or continent. Comparing data from different regions may reveal disparities in the severity of disease at the time of diagnosis, the treatments most often used, and short and long-term outcomes, which could inform the development of diagnosis and treatment guidelines, as well as public health policy to improve health equity and patient outcomes. Registries may also be useful for monitoring the real world impact and safety of new treatments, because they include data from high-risk patients, who are usually excluded from randomized controlled trials. 2 2 Eldh AC, Wallin L, Fredriksson M, Vengberg S, Winblad U, Halford C, et al. Factors facilitating a national quality registry to aid clinical quality improvement: findings of a national survey. BMJ Open. 2016;6(11):e011562. https://doi.org/10.1136/bmjopen-2016-011562 https://doi.org/10.1136/bmjopen-2016-011... Although registries are created mostly to inform clinical management, the accumulated data can be used in order to answer research questions. A registry-based study is an observational method to answer a research question using data from patient registries. Researchers can answer research questions using a patient registry to quickly access data provided by hundreds, or even thousands, of similar patients. In our practical scenario example, the researchers found that only 67% of patients in the Brazilian registry had access to genotyping tests, and that access to newborn screening and age at diagnosis were mediators of the effect that region had on a positive genotyping result. 1 1 da Silva Filho LVRF, Maróstica PJC, Athanazio RA, Reis FJC, Damaceno N, Paes AT, et al. Extensive CFTR sequencing through NGS in Brazilian individuals with cystic fibrosis: unravelling regional discrepancies in the country. J Cyst Fibros. 2021;20(3):473-484. https://doi.org/10.1016/j.jcf.2020.08.007 https://doi.org/10.1016/j.jcf.2020.08.00... Multiple studies may be performed by using a single patient registry. Although studies using patient registries are typically retrospective in nature, they have the advantage of including very broad study populations, thus providing results that are more frequently generalizable to the target population than are those of highly controlled randomized clinical trials. The differences between a patient registry and a registry-based study are shown in Table 1. Developing and implementing a registry is not an easy task. It requires human and financial resources to design and implement the project. Case finding and data collection are time consuming and demand adequate training and motivation of stakeholders, to ensure participation and the collection of reliable data. Those can be barriers, and financial and nonfinancial incentives or credits may be used. Sustainability of the project, with continued funding and data collection, also needs to be considered. Registries also need appropriate e -Abstract Truncated-

A systematic overview of rare disease patient registries: challenges in design, quality management, and maintenance

Establishing Patient Registries for Rare Diseases: Rationale and Challenges

The Gospel Oak Study stage III: the incidence of dementia

Recommendations for Improving the Quality of Rare Disease Registries

Framework for Multistakeholder Patient Registries in the Field of Rare Diseases: Focus on Neurogenetic Diseases

So You Want to Build Your Disease's First Online Patient Registry: An Educational Guide for Patient Organizations Based on US and European Experience

Scoping review of the recommendations and guidance for improving the quality of rare disease registries

The EuRRECa Project as a Model for Data Access and Governance Policies for Rare Disease Registries That Collect Clinical Outcomes

MDS patient registries - achievements and challenges

Lessons learned from the RE(ACT) conference on medical devices for rare diseases

Informing a national rare disease registry strategy in Australia: a mixed methods study

Using data from patient registries to answer important research questions

A qualitative study of design stakeholders' views of developing and implementing a registry-based learning health system

How to establish and sustain a disease registry: insights from a qualitative study of six disease registries in the UK

A rare partnership: patient community and industry collaboration to shape the impact of real-world evidence on the rare disease ecosystem

The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases

Data silos are undermining drug development and failing rare disease patients

Lessons from the Rare Diseases Registry and Analytics Platform framework for development of a national rare diseases registry for India

National information system for rare diseases with an approach to data architecture: A systematic review

Increase transparency and reproducibility of real‐world evidence in rare diseases through disease‐specific Federated Data Networks

Current situation and challenge of registry in China